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Background: The accurate and early diagnosis of acute myeloid leukemia (AML) is im-
portant to choose proper treatment option depending on the risk stratification. The delta 
neutrophil index (DNI) is a relatively new blood marker that indicates the proportion 
of immature granulocytes in peripheral blood circulation. This study aimed to evaluate 
the diagnostic value of the DNI for detecting AML in the early phase of acute leukemia.
Methods: We retrospectively analyzed laboratory tests and bone marrow study results 
of 163 pediatric patients with acute leukemia admitted to the emergency department, 
who were diagnosed with acute leukemia. An automatic analyzer (ADVIA 2120 
Hematology System; Siemens Healthcare Diagnostics, Forchheim, Germany) was used 
to measure the DNI in the peripheral blood of each patient.
Results: The mean DNI was significantly different between the AML (N=39) and non-AML 
(N=124) groups (P＜0.05), and the DNI was the only significant marker for predicting 
AML in patients with acute leukemia (odds ratio, 1.328; P＜0.05). The DNI more than 
4.4% has the highest predictability for distinguishing the patients with AML from the 
patients with acute leukemia. The mean DNI of the acute promyelocytic leukemia (APL, 
N=8) group was statistically higher than that of the non-APL group (N=31, P=0.019), 
but the DNI was not significant in the univariate logistic regression analysis.
Conclusion: The DNI might be a promising peripheral blood marker for predicting AML 
in the early work-up of patients with acute leukemia.
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Introduction
Acute leukemia is the most common malignant neoplasm 
occurring in childhood [1], and acute lymphoblastic leuke-
mia (ALL) is responsible for the majority (approximately 
80%) of childhood acute leukemia, whereas acute myeloid 
leukemia (AML) comprises the most of the rest [2]. Prior 
to the 1960’s, childhood ALL and AML had very low 5-year 
survival rates of ＜10% [3]. However, recent data from 
National Cancer Institute’s Surveillance, Epidemiology, and 
End Results Program showed that the 5-year event-free sur-
vival rate for children with ALL was up to 90% and for chil-
dren with AML was up to 66% [4,5]. Although diagnostic 
tools for leukemia have greatly improved in recent times, 
there are still several difficulties in accurately diagnosing 
acute leukemia, especially in children [6]. 
The delta neutrophil index (DNI) indicates the ratio of 
circulating immature granulocytes to total neutrophil count. 
The DNI is calculated using an automated blood cell ana-
lyzer [7] with two separate channels-the myeloperoxidase 
(MPO) channels and nuclear lobularity channels [8]. By 
subtracting the fraction of mature polymorphonuclear leu-
kocytes from the sum of the MPO-reactive cells, we can es-
timate the fraction of immature granulocytes such as meta-
myelocytes, myeloctyes and promyelocytes [9]. After the ap-
pearance of this new biological marker, many studies have 
aimed at identifying clinical relationships between the DNI 
and several diseases [9-15]. The DNI seems to have diag-
nostic and prognostic value for infectious diseases, includ-
ing sepsis and severe systemic inflammation. Furthermore, 
studies have reported associations between the DNI and 
rheumatologic diseases such as vasculitis [12-13]. However, 
thus far, only a few studies have focused on the importance 
of the DNI as marker for the myeoloid leukemia [14]. 
In this study, we aimed to determine the clinical sig-
nificance of the DNI as a new blood marker to distinguish 
AML from acute leukemia in children with acute leukemia. 
Materials and Methods
1) Study design and patients 
We retrospectively analyzed the medical records of 179 
pediatric patients (age 0-18 yr at the time of diagnosis) di-
agnosed with acute leukemia from January 2011 to October 
2016 at a single tertiary academic hospital. Of them, 16 pa-
tients were excluded from the study due to the lack of defi-
nite bone marrow confirmation results (blast count for ≥
20% from bone marrow aspiration or bone marrow patho-
logical confirmation). 
The results for complete blood count, DNI, routine 
chemistry laboratory results, C-reactive protein levels, lac-
tate dehydrogenase levels, aspartate transaminase (AST) 
levels, alanine aminotransferase (ALT) levels, bone marrow 
biopsy with aspiration, and cytogenetic analysis were as-
sessed for all eligible patients. According to the bone mar-
row study and cytogenetic analysis, we assorted all eligible 
patients into two groups: AML and non-AML. ALL and 
mixed-phenotype acute leukemia (MPAL) were classified as 
non-AML. We categorized ALL into three subgroups only 
according to cell linage and presence of philadelphia chro-
mosome to first screen whether further classification of ALL 
would be necessary: B linage ALL, T linage ALL, and ALL 
with the Philadelphia chromosome. The AML group was 
categorized as each subgroups according to the World 
Health Organization classification of AML [16].
2) The DNI and other variants
We collected laboratory data of all eligible patients from 
the peripheral blood specimens collected at the time of the 
visit to the pediatric emergency department. The DNI was 
calculated using an automatic cell analyzer (ADVIA 2120 
Hematology System, Siemens Healthcare Diagnostics, 
Forchheim, Germany) as per the following formula: 
DNI=[sum of the neutrophil sub-fraction and the eosinophil 
sub-fraction measured in the myeloperoxidase (MPO) chan-
nel]−(the polymorphic neutrophil sub-fraction measured in 
the nuclear lobularity channel). 
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Table 2. Comparison of clinical characteristics between the AML and non-AML patients 
Parameters
Total
(N=163)
Non-AML
(N=124)
AML
(N=39)
P-value
Age (yr) 7.94 (0.3-18) 7.61 (0.3-18) 8.99 (0.7-17.9) 0.18
WBC count (×103/L) 49219.8±97309.4 48750±95919.1 50713.3±102884.9 0.91
Hb (g/dL) 8.7±2.5 8.6±2.7 8.7±2.0 0.77
Plt count (×103/L) 106.4±102.32 114.4±109.5 80.9±70.3 0.027a)
LDH (IU/L) 1232.2±2184.9 1312.0±2383.5 978.5±1369.7 0.41
AST (IU/L) 52.9±101.7 60.6±115.3 28.4±17.3 0.003a)
ALT (IU/L) 43.5±119.2 51.0±135.7 19.6±15.7 0.013a)
CRP (mg/L) 27.4±42.1 28.1±39.8 25.3±49.2 0.72
DNI (%) 5.8±15.8 0.8±2.5 21.8±26.5 ＜0.001a)
a)P＜0.05. AML, acute myeloid leukemia; WBC, white blood cell; Hb, hemoglobin; Plt, platelet; LDH, lactate dehydrogenase; AST, 
aspartate transaminase; ALT, alanine aminotransferase; CRP, C-reactive protein; DNI, delta neutrophil index.
Table 1. Clinical characteristics and types of leukemia of total patient
Non AML (N=124) AML (N=39)
Gender Male 78 (63%) Male 21 (54%)
Female 46 (37%) Female 18 (46%)
Types ALL (N=122) B linage ALL 90 (73%) AML with t(8;21)(q22;q22) ; RUNX1/RUNX1T1 6 (15%)
AML with inv(16)(p13q22);CBFB-MYH11 2 (5%)
Acute promyelocytic leukemia t(15;17); PML/RARA 8 (21%)
T linage ALL 22 (18%) AML with mutated CEBPA 2 (5%)
AML with myelodysplasia-related changes 1 (3%)
Therapy-related myeloid neoplasm 1 (3%)
ALL with the 
Philadelphia 
chromosome
10 (7%) AML without maturation 4 (10%)
AML with maturation 7 (18%)
Acute myelomonocytic leukemia 5 (12%)
MPAL (N=2) 2 (2%) Acute monocytic leukemia 1 (3%)
Myeloid leukemia associated with Down syndrome 2 (5%)
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MPAL, mixed-phenotype acute leukemia.
3) Statistical analysis
Continuous variables were expressed as mean±standard 
deviation, and categorical variables were done as number 
and the percentage. Two-sample t-test or the Mann-Whitney 
U-test was used to compare the means of continuous varia-
bles between two groups. The univariate logistic regression 
analysis was used to examine the odds ratio (OR) of each 
independent variable predicting AML in patients with acute 
leukemia. Sensitivity and specificity along with predict-
ability of the DNI for distinguishing the patients with AML 
from the patients with acute leukemia was calculated using 
receiver operating characteristic (ROC) curve. The optimal 
cut-off value of the DNI was selected when Youden’s index 
(defined as sensitivity+specificity-1) was maximized. For all 
statistical analyses, SPSS software version 23 for windows 
(IBM Corp., Armonk, NY, USA) was used and P-values 
＜0.05 were considered statistically significant. 
Results
A total of 163 patients were eligible for this study and 
diagnosed with acute leukemia by bone-marrow study. Of 
these, 39 patients (24%) were diagnosed with AML, and the 
remaining patients were diagnosed with ALL (N=122, 75%) 
or MPAL (N=2, 1%) (Table 1). The percentage of male 
(N=21, 54%) did not differ much from that of female (N=18, 
46%) in AML patient group, while the percentage of male 
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Table 3. Univariate logistic regression analysis (AML vs non- 
AML)
Odds ratio (95% CI) P-value
Age (yr) 0.963 (0.866-1.072) 0.49
WBC count (×103/L) 1.000 (1-1) 0.395
Hb (g/dL) 1.020 (0.817-0.273) 0.861
Plt count (×103/L) 0.995 (0.989-1.002) 0.178
LDH (IU/L) 1.000 (0.999-1.000) 0.372
AST (IU/L) 0.973 (0.931-1.016) 0.215
ALT (IU/L) 0.779 (0.975-1.035) 0.779
CRP (mg/L) 0.992 (0.974-1.010) 0.386
DNI (%) 1.328 (1.155-1.527) ＜0.001a)
a)P＜0.05. AML, acute myeloid leukemia; WBC, white blood 
cell; Hb, hemoglobin; Plt, platelet; LDH, lactate dehydrogenase; 
AST, aspartate transaminase; ALT, alanine aminotransferase; 
CRP, C-reactive protein; DNI, delta neutrophil index. 
Fig. 1. Receiver operating characteristic (ROC) curves of delta
neutrophil index (DNI) for predicting AML. The area under the
ROC curve for distinguishing AML from acute leukemia is 0.815
(P＜0.01). The optimal cut-off of DNI using Youden’s index is 
4.4% (Sensitivity, 69.2%, specificity 94.4%).
(N=78, 63%) was relatively bigger than that of female’s 
(N=46, 37%) in non AML patients (Table 1). The age of 
total patients enrolled in the study varied from 0.25 to 18 
years old. The mean age of total patient group was 7.94 
and the mean age of AML (8.99) and non AML patient 
group (7.61) each did not show significant differences 
(P=0.18) (Table 2). Patients with ALL (N=122) were as-
sorted into three subgroups according to the lymphoid cell 
lineage and presence of the Philadelphia chromosome. 
Ninety (73%) of the 124 non-AML patients had B linage ALL 
and 22 (18%) had T linage ALL. The remaining 12 patients 
(9%) consisted of 10 Philadelphia ALL patients (7%) and 2 
mixed phenotype acute leukemia patients (2%) (Table 1). 
Comparison of variables between the AML and non-AML 
groups revealed that platelet count, AST, and ALT levels 
and mean DNI of the AML group were significantly differ-
ent from those of the non-AML group. However, WBC 
count, hemoglobin, LDH, and CRP level did not show sig-
nificant differences between two patient groups (Table 2). 
Of the four variables that showed significant differences, 
the mean DNI between the AML group (21.63±25.53) and 
non-AML group (0.80±2.49) was especially significant (P
＜0.001, Table 2). 
We evaluated each variable using the logistic regression 
model to determine their odds ratios for predicting AML in 
patients with acute leukemia. Among them, the DNI was 
the only statistically significant predictor of AML (OR, 1.328; 
95% CI; 1.155-1.527; P＜0.001), not the platelet count 
(P=0.178) or AST (P=0.215) and ALT (P=0.779) levels 
(Table 3). Subsequently, we used a ROC curve to examine 
the diagnostic accuracy of using the DNI to distinguish AML 
from acute leukemia; the area under the ROC curve showed 
a value of 0.815 (P＜0.01) (Fig. 1). According to our data 
regarding the ROC curve, the highest sensitivity for dis-
tinguishing AML from acute leukemia patient group was 
71.8% at the DNI value of 0.85% (Specificity, 83.1%). The 
optimal cut-off value of DNI using Youden’s index in this 
ROC curve was 4.4%, whereas the sensitivity was 69.2% 
and the specificity was 94.4%. Using the cut-off value of 
4.4% in our study, only 7 non-AML patients had peripheral 
blood DNI values over this cut-off value, whereas a ma-
jority of AML patients had DNI values above the cut-off val-
ue (Fig. 2). We listed all 7 non-AML patients and their clin-
ical characteristics who had the DNI value above 4.4%, the 
cut-off value suggested according to Youden’s index in 
Table 4. There were 3 B linage ALL patients (43%), 3 T 
linage ALL patients (43%), and 1 ALL patient with 
Philadelphia chromosome (14%). All 7 patients showed 
negative result for both blood and urine cultures meaning 
there were no proven bacterial infections. The immuno-
logic marker of anti-myeloperoxidase (MPO) was also neg-
ative in all 7 patients. However, the CRP levels were ‘posi-
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Table 4. Clinical characteristics of non AML patients with high DNI
Patient 
No.
Types of 
leukemia
Gender
Age 
(Yr)
WBC 
(×103/L)
DNI 
(%)
Blood 
culture
Urine 
culture
Anti-MPO
CRP 
(mg/L)
1 B linage ALL M 3.3 26,120 4.8 Negative Negative Negative 11.7
2 B linage ALL M 13 56,400 4.7 Negative Negative Negative 7.5
3 B linage ALL M 12.3 36,340 18.3 Negative Negative Negative 8.0
4 T linage ALL F 14.3 11,460 15.0 Negative Negative Negative 17.8
5 T linage ALL F 3.3 493,410 5.8 Negative Negative Negative 0.6
6 T linage ALL F 15.5 4,410 4.8 Negative Negative Negative 66.4
7 ALL with Ph F 6.8 5,080 8.4 Negative Negative Negative 72.2
ALL, acute lymphoblastic leukemia; WBC, white blood cell; CRP, C-reactive protein; DNI, delta neutrophil index; MPO, 
myeloperoxidase; Ph, Philadelphia chromosome. 
Fig. 2. The delta neutrophil index (DNI) according to the 
subgroup of acute leukemia. The marked line parallel to the 
“Types of leukemia” on the graph indicates a DNI of 4.4%, a 
cut-off value suggested in our study. Twenty nine of the 39 
patients with AML (74%) had a DNI ＞4.4% whereas only 7 
patients with ALL (5.6%) and no patients with MPAL had the 
DNI ＞4.4%. APL, acute promyelocytic leukemia; nP AML, non 
promyelocytic acute myeloid leukemia; AML, acute myeloid 
leukemia.
tive’ in 5 of 7 patients (71%, CRP level above 8 mg/L was 
counted meaningfully elevated) (Table 4). 
We divided the AML group into 11 subgroups according 
the World Health Organization classification of AML (Table 
1). Among the 39 patients with AML, 8 patients (21%) were 
diagnosed with acute promyelocytic leukemia (APL). The 
rest of each subgroup for AML had too small number of 
patients to analyze respectively. The mean age of APL and 
non APL group did not show any statistically meaningful 
differences (P=0.905). The mean DNI and lactate de-
hydrogenase level showed significant differences between 
the APL and non-APL groups among patients with AML 
(P=0.019 and P=0.015, respectively), while WBC count 
(P=0.152), platelet count (P=0.067), AST (P=0.851), ALT 
(P=0.772), and CRP level (P=0.328) did not (Table 5). 
However, according to the univariate logistic regression, 
none of the variables including LDH level (P=0.270) and 
the DNI level (P=0.085) had significant odds ratio for pre-
dicting APL from AML patients (Table 6).
Discussion
The DNI is a new blood marker that represents the pro-
portion of immature granulocytes in the peripheral circu-
lation and is unfamiliar to clinicians worldwide [7]. To date, 
several studies have reported the DNI as an effective diag-
nostic and prognostic marker of sepsis and severe systemic 
inflammation [9-12]. Since the DNI is calculated by subtract-
ing the number of multi-lobulated blood cells from the sum 
of MPO-positive blood cells, all disease conditions that in-
crease the number of MPO-positive cells in blood circu-
lation could show high peripheral blood DNIs. The under-
standing MPO and MPO-rich cells is critical to interpreting 
the clinical meaning of the DNI and its relationship with 
such diseases. 
The MPO is a peroxidase enzyme most abundantly ex-
pressed in polymorphonuclear neutrophils that produce hy-
pochlorous acid, a potent oxidant with antimicrobial activ-
ity in the human body [17]. Many studies have thus far 
highlighted the clinical significance of the MPO in various 
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Table 5. Comparison of clinical characteristics between the APL and non-APL patients 
APL (N=8) Non-APL (N=31) Total (N=39) P-value
Age (yr) 9.0 (1.25-17.1) 9.0 (0.7-17.92) 9.0 (0.7-17.92) 0.905
WBC count (×103/L) 15518.8±17079.3 59795.8±113685.8 50713.3±102884.9 0.152
Hb (g/dL) 8.1±1.7 8.9±2.1 8.7±2.0 0.597
Plt count (×103/L) 46±41.8 89.9±73.8 80.9±70.3 0.067
LDH (IU/L) 459.1±299.6 1112.6±1504.9 978.5±1369.7 0.015a)
AST (IU/L) 26.3±8.8 28.9±18.9 28.4±17.3 0.851
ALT (IU/L) 20.5±16.7 19.4±15.7 19.6±15.7 0.772
CRP (mg/L) 39.3±86.1 21.7±35.6 25.3±49.2 0.328
DNI (%) 46.1±39.7 15.5±17.9 21.8±26.5 0.021a)
a)P＜0.05. APL, acute promyelocytic leukemia; AML, acute myeloid leukemia; WBC, white blood cell; Hb, hemoglobin; Plt, platelet; 
LDH, lactate dehydrogenase; AST, aspartate transaminase; ALT, alanine aminotransferase; CRP, C-reactive protein; DNI, delta 
neutrophil index. 
Table 6. Univariate logistic regression analysis (APL and non- 
APL groups)
Odds ratio 
(95% confidence interval)
P-value
Age (yr) 0.846 (0.586-1.221) 0.371
WBC count (×103/L) 1.000 (0.999-1) 0.352
Hb (g/dL) 1.372 (0.456-4.123) 0.573
Plt count (×103/L) 1.004 (0.980-1.028) 0.751
LDH (IU/L) 0.992 (0.979-1.006) 0.270
AST (IU/L) 0.923 (0.684-1.246) 0.601
ALT (IU/L) 1.085 (0.919-1.280) 0.336
CRP (mg/L) 1.033 (0.980-1.089) 0.227
DNI (%) 1.113 (0.985-1.258) 0.085
APL, acute promyelocytic leukemia; AML, acute myeloid 
leukemia; WBC, white blood cell; Hb, hemoglobin; Plt, 
platelet; LDH, lactate dehydrogenase; AST, aspartate trans-
aminase; ALT, alanine aminotransferase; CRP, C-reactive pro-
tein; DNI, delta neutrophil index.
diseases including non-infectious diseases [18,19]. In addi-
tion, as the specific expression of the MPO is restricted only 
to myeloid precursors and leukemic cells, the diagnosis of 
hematologic malignancies of myeloid cell origin, such as 
AML, involves the use of MPO staining and MPO messenger 
RNA expression as an immunochemistry marker [20]. Thus, 
since the lymphoblasts and lymphoid lineage cells usually 
do not express MPO, this enzyme could be a good bio-
logical marker for distinguishing AML among patients with 
acute leukemia. Peripheral blood DNI, which indirectly re-
flects the percentage of MPO-expressing cells in peripheral 
circulation, is expected to be higher in patients with AML 
than in those with ALL. This might explain the results from 
our study, which showed significantly higher peripheral 
blood DNIs in the AML group compared to the non-AML 
group; and an OR of 1.328 for peripheral blood DNI as a 
predictor of AML in patients with acute leukemia (P
＜0.001). 
In our study, 28 of the 122 patients with ALL (24%) 
showed elevation of the DNI (＞0%). Of these, 7 patients 
with ALL (6%) had a peripheral blood DNI above the 
cut-off DNI of 4.4% for distinguishing AML from acute 
leukemia. Surprisingly, we observed a relatively high DNI 
in patients with ALL, although lymphoid lineage cells usu-
ally do not express MPO and are therefore expected to 
have a DNI of approximately 0%. Such a high peripheral 
blood DNI in patients with ALL may be explained by the 
following reasons. First, patients with ALL concurrently hav-
ing infectious diseases at the early phase can yield relatively 
high peripheral blood DNIs. Although patients with ALL do 
not show MPO-positive cells, the presence of infectious dis-
eases could lead to expression of MPO-abundant neu-
trophils, providing a high peripheral blood DNI in the labo-
ratory findings. Another explanation is MPO-expressing 
B-cell ALL. Thus far, several studies worldwide have re-
ported patients with ALL expressing the MPO [21,22]. 
Oberley et al. reported a study on isolated MPO expression 
in pediatric patients with B-cell ALL and its clinical sig-
nificance [23]. They concluded that patients with B-cell ALL 
who expressed MPO had an increased rate of relapse and 
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a worse event-free survival than patients with B-cell ALL 
who did not express MPO. In our study, 7 patients with 
ALL who showed relatively high peripheral blood DNIs, 3 
patients had B linage ALL, 3 patients had T linage ALL, and 
1 patient had ALL with the Philadelphia chromosome. None 
of the 7 patients showed anti-MPO expression in the im-
muno-chemistry examination while 5 of 7 patients (71%) 
had ‘positive’ CRP levels assuming presence of infectious 
conditions. Thus, we concluded that there were no isolated 
MPO-expressing B-cell ALL patients in our patient pool and, 
that the patients with ALL showing relatively high periph-
eral blood DNIs are likely due to the presence of in-
flammatory conditions.
Thus far, two studies attempted to determine the diag-
nostic significance of the DNI in the context of acute 
leukemia. Jang et al. did not show significant differences 
in the DNI of bone marrow between the APL and non-APL 
groups [24]. In contrast, Ko et al. showed that the periph-
eral blood DNIs of the APL group were significantly higher 
than those of non-APL group and suggested that the pe-
ripheral blood DNI in early-stage APL could be an in-
dependent predictor of APL [14]. Contrary to the findings 
of Ko et al., our study showed that the peripheral blood 
DNI values can be a useful marker for predicting AML 
among children with acute leukemia in the early phase of 
disease. To our knowledge this is the first study not only 
to examine the efficacy of the DNI as diagnostic marker 
for hematologic malignancies in children, but also to eval-
uate and document the possible usefulness of peripheral 
blood DNI for distinguishing AML from pediatric acute leu-
kemia patients. In addition, comparison of the peripheral 
blood DNI between the APL and non-APL groups did not 
reveal any significant difference. One of the possible rea-
sons for this might be the small number of total APL (N=8) 
and non-APL (N=31) patients enrolled in the study, which 
failed to yield meaningful statistical output. To date, 
bone-marrow studies with cytogenetic analyses are the gold 
standard for diagnosing acute leukemia. However, some 
difficulties and pitfalls persist in bone-marrow study alone 
for such early distinction and accurate diagnosis of acute 
leukemia [6,15], especially in children who have to undergo 
general anesthesia for bone-marrow studies. Although pe-
ripheral blood DNI cannot be a confirmatory test, it can 
be a faster and easier screening test to provide an early esti-
mation of AML from acute leukemia patients even in the 
emergency department. Consequently, with the help of pe-
ripheral blood DNI as an early screening ancillary test of 
bone marrow, timely risk-stratification and accurate diag-
nosis are possible, which could lead to early treatment ini-
tiation of acute leukemia in children and a better outcome.
Despite our important findings, this study has several 
limitations. First, it is a retrospective study with a small 
number of patients. Thus, selection bias may exist in our 
results. Second, we could not sufficiently examine the in-
flammatory signs and laboratory tests to exclude infectious 
diseases in each patient. Although the blood cultures, urine 
cultures, and blood C-reactive protein levels were consid-
ered, other parameters were not examined enough to prop-
erly determine the isolated effects of infection or systemic 
inflammation on patients’ DNIs. Third, as mentioned ear-
lier, the number of patients in the MPAL and APL groups 
was too small to yield a statistically significant output. In 
patients with MPAL, in particular, we did not find any stat-
istically significant results, as there were only 2 patients 
who had the DNI value of 0% and 4.2%, respectively. 
Theoretically, patients with MPAL are expected to have 
higher peripheral blood DNIs than patients with ALL, since 
the former express the MPO. Therefore, although the in-
cidence of MPAL is low, MPAL should be considered a pos-
sible diagnosis in patients with acute leukemia who have 
relatively high peripheral blood DNIs. Finally, since the 
number of total AML patients was small, the sensitivity of 
DNI as an early marker for distinguishing AML from acute 
leukemia patients was relatively low. Actually, our study 
produced up to 71.8% of sensitivity which is relatively low 
to state the superiority of DNI as a good screening marker. 
However, we carefully believe that with more number of 
AML patients in the study, the DNI might yield a better 
results. 
In conclusion, although this study was conducted with 
small number of patients and came out with relatively low 
sensitivity of DNI cut-off result, DNI may be a blood marker 
for AML, and its estimation in the early phase of a diag-
nostic work-up could be helpful for distinguishing AML 
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from children with acute leukemia. The DNI can be a sub-
sidiary tool for rapid recognition of AML, resulting in timely 
risk-stratification and treatment initiation. With further pro-
spective, multicenter studies on DNI in other subgroups of 
patients with AML, DNI can be a promising diagnostic and 
differentiation marker for predicting AML in acute leukemia 
patients and its clinical outcome.
Acknowledgments
Kang Hansung contributed in research planning as part of 
Medical Student Research program 2016 (Annals of Yonsei Medical 
Student Research, Vol 2, Page 217, 2017).
References
1. Linabery AM, Ross JA. Trends in childhood cancer incidence 
in the U.S. (1992-2004). Cancer 2008;112:416-32.
2. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood 
and adolescent cancer statistics, 2014. CA Cancer J Clin 
2014;64:83-103.
3. National Cancer Institute. Cancer incidence and survival 
among children and adolescents: United States SEER Program 
1975-1995. Bethesda, MD: National Cancer Institute, 1999. 
(Accessed September 2, 2018, at https://seer.cancer.gov/ar-
chive/publications/childhood/childhood-monograph.pdf)
4. Keegan TH, Ries LA, Barr RD, et al. Comparison of cancer 
survival trends in the United States of adolescents and young 
adults with those in children and older adults. Cancer 
2016;122:1009-16.
5. Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival 
after diagnosis with childhood hematologic malignancies in the 
United States, 1990-2004. J Natl Cancer Inst 2008;100: 1301-9.
6. Chessells JM; haemostasis and thrombosis task force, British 
committee for standards in haematology. Pitfalls in the diag-
nosis of childhood leukaemia. Br J Haematol 2001;114:506-11.
7. Kratz A, Maloum K, O'Malley C, et al. Enumeration of nucleat-
ed red blood cells with the ADVIA 2120 Hematology System: 
an International Multicenter Clinical Trial. Lab Hematol 
2006;12:63-70.
8. Fang DZ, Sran G, Gessner D, et al. Cost and turn-around time 
display decreases inpatient ordering of reference laboratory 
tests: a time series. BMJ Qual Saf 2014;23:994-1000.
9. Nahm CH, Choi JW, Lee J. Delta neutrophil index in auto-
mated immature granulocyte counts for assessing disease se-
verity of patients with sepsis. Ann Clin Lab Sci 2008;38:241-6.
10. Ahn C, Kim W, Lim TH, Cho Y, Choi KS, Jang BH. The delta 
neutrophil index (DNI) as a prognostic marker for mortality 
in adults with sepsis: a systematic review and meta-analysis. 
Sci Rep 2018;8:6621.
11. Nam M, Son BH, Seo JE, Kim IR, Park CK, Kim HK. Improved 
diagnostic and prognostic power of combined delta neu-
trophil index and mean platelet volume in pediatric sepsis. 
Ann Clin Lab Sci 2018;48:223-30.
12. Park JH, Byeon HJ, Lee KH, et al. Delta neutrophil index 
(DNI) as a novel diagnostic and prognostic marker of in-
fection: a systematic review and meta-analysis. Inflamm Res 
2017;66:863-70.
13. Yoo J, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW. Delta 
neutrophil index is associated with vasculitis activity and risk 
of relapse in ANCA-associated vasculitis. Yonsei Med J 
2018;59:397-405.
14. Ko DR, Jang JE, Chung SP, et al. Usefulness of the delta neu-
trophil index as an ancillary test in the emergency department 
for the early diagnosis of suspected acute promyelocytic 
leukemia. Leuk Lymphoma 2017;58:2387-94.
15. Yoon SH, Kim SH, Lee MJ, Lee HJ, Lyu CJ, Kim MK. A 
4-year-old girl presenting with facial palsy, found to have in-
creased delta neutrophil index, and diagnosed with acute 
myeloid leukemia with extramedullary infiltration. Pediatr 
Emerg Med J 2017;4:25-8.
16. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to 
the World Health Organization classification of myeloid neo-
plasms and acute leukemia. Blood 2016;127:2391-405.
17. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 
2005;77:598-625.
18. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: 
an oxidative pathway for generating dysfunctional high-den-
sity lipoprotein. Chem Res Toxicol 2009;23:447-54.
19. Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S. 
Growing significance of myeloperoxidase in non-infectious 
diseases. Clin Chem Lab Med 2002;40:2-8.
20. Crisan D, David D, DiCarlo R. Use of myeloperoxidase mRNA 
as a marker for myeloid lineage in acute leukemias. Arch 
Pathol Lab Med 1996;120:828-34.
21. Rytting ME, Kantarjian H, Albitar M. Acute lymphoblastic leu-
kemia with Burkitt-like morphologic features and high myelo-
peroxidase activity. Am J Clin Pathol 2009;132:182-5.
22. Zhou M, Findley HW, Zaki SR, Little F, Coffield LM, Ragab 
AH. Expression of myeloperoxidase mRNA by leukemic cells 
from childhood acute lymphoblastic leukemia. Leukemia 
1993;7:1180-3.
23. Oberley MJ, Li S, Orgel E, Phei Wee C, Hagiya A, O'Gorman 
MRG. Clinical significance of isolated myeloperoxidase expression 
in pediatric B-lymphoblastic leukemia. Am J Clin Pathol 
2017;147:374-81.
24. Jang MJ, Choi HW, Lee SY, et al. Application of bone marrow 
samples for discrimination of acute promyelocytic leukemia from 
other types of acute leukemia using the routine automated hema-
tology analyzer. Int J Lab Hematol 2014;36:531-40.
